An eight-week, randomized, double-blind comparison of guanfacine, focalin XR [extended release], and the combination, with a twelve month open-label extension for the treatment of ADHD [attention-deficit hyperactivity disorder] in pediatric subjects aged 7 to 14 years.

Trial Profile

An eight-week, randomized, double-blind comparison of guanfacine, focalin XR [extended release], and the combination, with a twelve month open-label extension for the treatment of ADHD [attention-deficit hyperactivity disorder] in pediatric subjects aged 7 to 14 years.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Dexmethylphenidate (Primary) ; Guanfacine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2008 Updated lead investigator, from NCT.
    • 06 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top